Tech Mahindra Expands Relationship with Covisint to Utilize Covisint's IoT Platform to Create Vertical Solutions
Global Partnership Drives Digital Business Transformation by Securely Connecting Complete Ecosystems of People, Systems and Things
DETROIT, April 20, 2017 (GLOBE NEWSWIRE) -- Covisint Corporation (Nasdaq:COVS) and Tech Mahindra, a leader in digital transformation for the Telecommunications and Manufacturing industries, today announced that Tech Mahindra will be using the Covisint IoT Platform to enable digital transformation solutions across a variety of IoT initiatives - including smart cities, and the telecommunications and automotive markets.
Through this partnership, there will be a focused solution building and joint go-to-market efforts around:
Smart Cities - Diverse technologies need to be integrated to connect smart city ecosystems and realize the full potential of large-scale smart city initiatives. Tech Mahindra is an early innovator in this evolving market.
Telecommunications - The vast ecosystem around telco providers brings upon many disparate technology stacks - that need to act as one to help realize the full benefits of connected initiatives. Solutions that result from the new expansion of the Tech Mahindra and Covisint relationship will be aimed squarely at solving this problem.
Automotive - Both Tech Mahindra and Covisint have a long heritage in the Automotive space. The two companies will be creating solutions that will focus on the Connected Vehicle and Supply Chain markets.
"We are excited to be a part of this initiative and we are confident that this collaboration will provide us a distinct edge with alliances and customers. Leveraging Covisint's cloud-based platform and Tech Mahindra's expertise in IoT and digital transformation opens up promising vistas for us," said Karthikeyan Natarajan, Global Head, Engineering, IoT and Enterprise Mobility at Tech Mahindra.
The Covisint IoT Platform - delivered as a platform-as-a-service (PaaS) at scale with global support - offers a complete set of capabilities required to rapidly build enterprise IoT solutions, including advanced identity, authentication, authorization, real-time messaging and orchestration, as well as digital ecosystem definition and management capabilities to facilitate secure information sharing and trusted interactions with the world around that connected asset. Covisint's IoT Platform brings together a set of foundational capabilities that helps businesses rapidly deliver IoT solutions supportive of digital transformation, including:
A unified data model that brings together the devices, the systems and the people that interact with into one coherent logical data store.
Dynamic security that helps businesses respond quickly and contextually to deliver better value, while minimizing security risk.
Unified messaging that brings together messaging and orchestration in both real-time and batch interactions to effectively digitize end-to-end business processes.
API-first approach for enabling agnostic and loosely coupled business service integration for complex transformations.
A microservices architecture to meet the scalability demands of billions of connected devices and digital businesses.
"We couldn't be more excited about what we can achieve together with Tech Mahindra, as our partnership has already produced great benefits for both companies," said Joel Kremke, SVP of Partnerships and Alliances, Covisint. "We believe the expanded alliance can be one of the largest in the IoT market, and will provide both organizations a whole new path to creating value for the market and for both of our customers. Tech Mahindra are not only market leaders but are also thought leaders in all of the verticals that we're pursuing with them - it's an honor to be working with them."
About Covisint Corporation
Covisint is the connected company - we securely connect ecosystems of people, systems and things to enable new service offerings, optimize operations, develop new business models and ultimately enable the connected economy. Today, we support more than 2,000 organizations and connect to more than 212,000 business partners and customers worldwide. Learn more at www.covisint.com.
About Tech Mahindra
Tech Mahindra represents the connected world, offering innovative and customer-centric information technology experiences, enabling Enterprises, Associates and the Society to Rise(TM). We are a USD 4.2 billion company with 117,000+ professionals across 90 countries, helping over 837 global customers including Fortune 500 companies. Our convergent, digital, design experiences, innovation platforms and reusable assets connect across a number of technologies to deliver tangible business value and experiences to our stakeholders. Tech Mahindra is amongst the Fab 50 companies in Asia (Forbes 2016 list).
We are part of the USD 17.8 billion Mahindra Group that employs more than 200,000 people in over 100 countries. The Group operates in the key industries that drive economic growth, enjoying a leadership position in tractors, utility vehicles, after-market, information technology and vacation ownership.
Connect with us on www.techmahindra.com
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding Covisint's present and future technology design, architecture, performance and operations which affects the Covisint IoT Platform's market growth and the demand for Covisint's solutions. Any forward-looking statements contained in this press release are based upon Covisint's historical performance and its current plans, estimates and expectations and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Covisint's expectations as of the date of this press release. Subsequent events may cause these expectations to change, and Covisint disclaims any obligation to update the forward-looking statements in the future except as may otherwise be required by the federal securities laws. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, our ability to work with Tech Mahindra to attract new customers; the continued growth of the market for these solutions; competition from current competitors and new market entrants; unpredictable macro-economic conditions; the loss of any of our key employees; and the length of the sales for our solutions. Further information on potential factors that could affect actual results is included in Covisint's reports filed with the SEC.
Investor Relations Contact
Brad Schechter, Vice President, Corporate Marketing
Shalini Singh, Global Media Relations & PR
Covisint Corporation, 26533 Evergreen Road, Suite 500, Southfield, MI 48076, 800-229-4125
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Covisint Corporation via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference21.9.2017 14:00 | Pressmeddelande
AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company's Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time. About True Human(TM) Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. About XBiotech
At the 10th anniversary of the iPhone, Chairman of Pilatus Bank draws a stark comparison of the role technology has played in banking vs telecommunication21.9.2017 08:58 | Pressmeddelande
LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Ali Sadr, Chairman of Pilatus Bank, believes that banks have failed to capture the true essence of technology for improving quality of service, as well as lacking the vision necessary to capture customers' imaginations. Meanwhile, other industries have been revolutionized and continue to thrive by the same technology. America has in the last 10 years been forced to close 10,000 branches. Since 2008, Europe has lost close to 48,000 branches, which is more than 20% of its branch network. There is little doubt that branch banking is on the decline, and online banking is failing to provide a quality service. As we mark the 10th anniversary of the iPhone, Ali Sadr, Chairman of Pilatus Bank, gives a sobering count of the current state of affairs in the use of technology among well established banks, and elaborates on a vision that has the potential to become the largest revolution the banking industry is yet to experience. Chairman Al
Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA21.9.2017 08:00 | Pressmeddelande
Pressmeddelande 21 september 2017 Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA Immunicum AB (publ; First North Premier: IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörer, meddelar idag att Society for Immunotherapy of Cancer (SITC) har accepterat att ett abstract kring ilixadencels verkningsmekanism presenteras som poster vid SITCs 32:a årsmöte som hålls 8-12 november, 2017 i Gaylord National Hotel & Convention Center i National Harbor, Maryland. Postern med titeln "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" presenteras av Immunicums forskningschef Alex Karlsson-Parra. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande efter presentationen. När datum och tidpunkt för presentationen offentliggjorts kommer detta att fi
Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US21.9.2017 08:00 | Pressmeddelande
Press Release 21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that the Society for Immunotherapy of Cancer (SITC) has accepted an abstract on ilixadencel's mode of action for a poster presentation at the SITC 32 nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" will be presented by Immunicum's Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will announce the complete data through a press relea
Asure Software to Attend at Quora Consulting's Smartworking Summit21.9.2017 07:00 | Pressmeddelande
Asure Join's Industry Leaders to Discuss "Understanding the Productivity Enigma" AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Asure Software, (NASDAQ:ASUR), a leading provider in human capital management and workspace management software, will be sponsoring Quora Consulting's Smartworking Summit in central London, September 28th 2017. These summits have continued to lead in addressing work space issues, such as occupancy, utilization, and productivity in the workforce. Dominic Jackson, Asure Sales Director of EMEA commented, "It is workplace issues like productivity that have driven thought leadership here at Asure." He continued "Utilization of workspace solutions help you recruit and retain the best talent, improve employee productivity, streamline operations, and realize a significant ROI on your most valuable assets - people, space and technology. We are thrilled to be not only part of the discussion, but part of the solu
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure21.9.2017 00:23 | Pressmeddelande
DANVERS, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed's platform of PMA approved devices. With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure as stated in the indication: The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device impl
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum